Table 1. Patient characteristics at screening.
| Characteristic | n/N (%) | |
|---|---|---|
| Age [years], mean (± SD) | 49.4 | (± 12.7) |
| ≤ 50 years | 22/41 | (53.7) |
| > 50 years | 19/41 | (46.3) |
| Gender | ||
| Male | 14/41 | (34.1) |
| Female | 27/41 | (65.9) |
| Race | ||
| Caucasian | 41/41 | (100.0) |
| BMI [kg/m2], mean (± SD) | 23.7 | (± 4.4) |
| BMI ≥ 25 (overweight)* | 11/32 | (34.4) |
| Fibrosis stage | ||
| No fibrosis | 15/41 | (36.6) |
| F1 stage | 26/41 | (63.4) |
| Source of HCV infection† | ||
| IV drug use | 18/41 | (43.9) |
| Tattoos or piercings | 5/41 | (12.2) |
| Sexual transmission | 3/41 | (7.3) |
| Transfusions | 3/41 | (7.3) |
| Other | 5/41 | (12.2) |
| Unknown | 13/41 | (31.7) |
| HCV genotype | ||
| Genotype 1a | 24/41 | (58.5) |
| Genotype 1b | 17/41 | (41.5) |
| Smoking and alcohol consumption | ||
| Smokers | 21/38 | (55.3) |
| Consume alcohol | 25/39 | (64.1) |
| Laboratory markers, mean (± SD) | ||
| HCV RNA level [log10 IU/mL], n = 38 | 6.6 | (± 6.8) |
| AST [U/L], n = 38 | 40.7 | (± 21.0) |
| ALT [U/L], n = 38 | 48.0 | (± 28.2) |
| Total bilirubin [μmol/L], n = 37 | 11.7 | (± 6.3) |
| Hemoglobin [g/L], n = 26 (normal range: 120–180 g/L) | 143.6 | (± 15.0) |
| Creatinine [μmol/L], n = 38 (normal range: 44–106 μmol/L) | 67.3 | (± 12.9) |
| Ferritin [μg/L], n = 22 (normal range: 30–200 μg/L) | 172.4 | (± 130.4) |
| TSH [mU/L], n = 24 (normal range: 0.3–3.5 mU/L) | 1.7 | (± 1.3) |
| Fasting glucose [mmol/L], n = 26 (normal range: 3.9–5.6 mmol/L) | 5.0 | (± 0.6) |
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; HCV = hepatitis C; IV = intravenous; RNA = ribonucleic acid; SD = standard deviation; TSH = thyroid stimulating hormone.
† Multiple answers were reported
*BMI data only available for 32 patients